INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...

Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered via ...

Eli Lilly & Co. said Wednesday Emgality injection was approved by the U.S. Food and Drug Administration for the treatment of episodic cluster headache in adults. Lilly said Emgality is the first and ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its CGRP antibody, Emgality injection (300 mg) for the preventive treatment of episodic cluster headache in adult patients.

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...

England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. But they just made an exception for one of those companies: ...

Eli Lilly's Emgality didn't just hit the next-generation migraine market in third place behind Amgen and Novartis' Aimovig and Teva's Ajovy. It's been trailing its CGRP rivals in early sales results, ...

The approval was based on data from 3 randomized, double-blind, placebo-controlled trials (EVOLVE-1, EVOLVE-2, REGAIN) in patients with either episodic or chronic migraine. The Food and Drug ...

The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with episodic migraine deserve broad access to effective treatments "These ...